| 1. |
Reverse vaccinology enhances identification of vaccine candidates |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1392,
2003,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 2. |
Recommendations for administering Wyeth's pneumococcal conjugate vaccine CRM197 [`Prevnar'] have been reinstated to a 4-dose series by the US ACIP.* |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1392,
2003,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 3. |
Paediatric antiemetic use common in acute gastroenteritis |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1392,
2003,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 4. |
Sildenafil confers HMO member satisfaction for small rise in costs |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1392,
2003,
Page 5-6
L Hunt,
Preview
|
|
摘要:
It is estimated that erectile dysfunction (ED) affects approximately 30 million men in the US, with nearly 50% of men affected aged 40−70 years. Sildenafil has been shown to be a well-tolerated and efficacious oral therapy since its 1998 approval for use in men with ED of various etiologies. Consequently, sildenafil has contributed to the debate about appropriate insurance coverage of drugs within pharmacy-benefit plans. US-based investigators evaluated the economic effect of sildenafil coverage on prescription benefit plans across the US, and presented their findings at the 8th International Meeting of the International Society for Pharmacoeconomics and Outcomes Research [Arlington, Virginia, US; May 2003].
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 5. |
Ethinylestradiol/norethisterone worth it for menopausal symptoms |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1392,
2003,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 6. |
Treatment with anti-EGFR monoclonal antibody*†is beneficial in the treatment of head and neck cancer, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1392,
2003,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 7. |
Phenoxodiol shows promising antitumour activity |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1392,
2003,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 8. |
Duloxetine: dual action dulls pain in diabetic neuropathy and depression |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1392,
2003,
Page 9-11
RM Poole,
Preview
|
|
摘要:
Duloxetine [`Cymbalta'], a serotonin/norepinephrine reuptake inhibitor (SNRI), is effective in the treatment of pain caused by diabetic neuropathy, and also painful physical symptoms in patients with depression, according to studies presented at the 156th Annual Meeting of the American Psychiatric Association [San Francisco, US; May 2003]. The first study, involving more than 400 patients with diabetic neuropathy, showed that duloxetine provided significant, dose-dependent improvements in pain scores from as early as the first week of treatment, and was well tolerated, with the 60 mg/day dosage showing the most favourable risk-benefit profile. Analyses of pooled data from two studies involving nearly 500 patients with depression showed that duloxetine significantly reduced overall pain, back pain and shoulder pain, and that there was a correlation between this pain response, and the remission of emotional symptoms.
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 9. |
Betacarotene, tocopherol: no additional cardiovascular benefits |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1392,
2003,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 10. |
Atorvastatin confers significant cardiovascular benefit in patients with type 2 diabetes mellitus and no previous history of heart disease or stroke, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1392,
2003,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
首页
